Clinical Trial Update: RC48-ADC in HER2-low Advanced Breast Cancer [NA]

View source ↗

Summary

A clinical trial update indicates that RC48-ADC is being studied in HER2-low advanced breast cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RenJi Hospital | Conditions: Advanced Breast Cancer | NA | Status: RECRUITING